Time Restricted Eating (TRE) in Bipolar Disorder
TREBD
1 other identifier
interventional
40
0 countries
N/A
Brief Summary
This is a randomized controlled trial investigating the effects of an 8-TRE intervention compared to a wait list (control) on metabolic health and body composition in people diagnosed with BD and who are currently obese and at least mildly depressed. Following a 1-week baseline assessment, participants will be randomized to either a TRE or the wait list (1-to-1 ratio) for 8 weeks. At baseline, Week 8 (post treatment), and Week 20 (follow-up), investigators will assess daily eating patterns for one week, followed by collection of fasting lipids, body weight and vital signs. At Week 4 (i.e., mid-treatment), the investigators will assess self-reported outcomes only. Participants assigned to the wait list condition will have the option of receiving the TRE intervention after 20 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 26, 2025
CompletedFirst Posted
Study publicly available on registry
October 7, 2025
CompletedStudy Start
First participant enrolled
June 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2026
Study Completion
Last participant's last visit for all outcomes
September 30, 2027
May 5, 2026
May 1, 2026
4 months
September 26, 2025
May 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Weight Loss
Body weight will be collected in the fasted state using a digital scale (lbs)
Week 0, Week 8, Week 20
Secondary Outcomes (8)
Patient Health Questionnaire-9 (PHQ-9)
Week 0, Week 4, Week 8, Week 20
Generalized Anxiety Disorder scale (GAD-7)
Week 0, Week 4, Week 8 and Week 20
Pittsburgh Sleep Quality Index (PSQI)
Week 0, Week 4, Week 8, Week 20
Cognitive complaints in bipolar disorder rating assessment (COBRA)
Week 0, Week 4, Week 8, Week 20
Patient-reported Outcome Measurement Information System (PROMIS) Cognitive Function Short Form 8a
Week 0, Week 4, Week 8, Week 20
- +3 more secondary outcomes
Study Arms (2)
Time Restrictive Eating Condition
ACTIVE COMPARATORTRE is a dietary intervention where participants eat all of their food within a specific 8-hour eating window, for example eating only between 10am and 6pm. Participants will not be asked to change what they eat, only when to eat. Participants will keep a daily Food Timing Log to record the time of the first and last food and drink that they consume each day. The study will ask participants to continue to do this daily throughout the study (\~8 weeks).
Waitlist Condition
NO INTERVENTIONParticipants assigned to the wait list condition will have the option of receiving the TRE intervention after 20 weeks.
Interventions
Eligibility Criteria
You may qualify if:
- Adults (aged 18-65 years)
- Diagnosed with bipolar disorder (i.e., subtype Bipolar I or II as assessed with the Quick SCID)21
- Currently experiencing depression (i.e., PHQ-9 ≥ 10)22
- Currently overweight (i.e., Body mass index (BMI) \> 30 kg/m2)
- Provides Informed Consent
You may not qualify if:
- Dietary factors:
- Diagnosis, or strong clinical suspicion, of eating disorders, including but not limited to, anorexia nervosa, bulimia nervosa, binge eating disorder (as assessed with the Quick SCID)
- Concurrent dietary intervention or modification unrelated to study procedures
- Psychiatric factors:
- Severe depression (i.e., PHQ-9\>20)
- Experiencing manic symptoms (i.e., ASRM \< 6)23
- Active suicidal ideation (i.e., PHQ-9, item 9 \>2)
- Current alcohol/substance use disorder (as assessed with the Quick SCID)
- Medical factors:
- Use of weight loss medications or supplements
- Use of medications that may cause weight loss or gain, unless body weight and medication usage remained stable for at least 6 months
- Previous weight loss surgery
- Malignancy within past 2 years
- Major surgery within past 3 months
- Medical instability considered to interfere with study procedures
- +7 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Brigham and Women's Hospitalcollaborator
- Massachusetts General Hospitallead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Louisa G. Sylvia, PhD
Massachusetts General Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Director
Study Record Dates
First Submitted
September 26, 2025
First Posted
October 7, 2025
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
September 30, 2027
Last Updated
May 5, 2026
Record last verified: 2026-05